KK. Marija*a (Dr), H. Brunnströma (Prof), J. Kosieradzkia (Dr), L. Eka (Dr), J. Staafb (Ms), S. Baratha (Dr), P. Mariab (Prof)

a Department of Respiratory Diseases and Allergology, Skåne University Hospital, Lund, SWEDEN ; b Division of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, Lund, SWEDEN

* Marija.Kotevska@med.lu.se

Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive bronchoscopic procedure, well established as a diagnostic modality of first choice for diagnosis and staging of non-small cell lung cancer (NSCLC). The therapeutic decisions for advanced NSCLC require comprehensive profiling of actionable mutations, which is currently considered to be an essential part of the diagnostic process.

Objectives: The purpose of this study was to evaluate the utility of EBUS-TBNA cytology specimen for simoultaneous histological subtyping, molecular profiling of NSCLC by massive parallel sequencing (MPS), as well as for PD-L1 analysis.

Materials and methods: A retrospective review of 806 EBUS bronchoscopies was performed, resulting in a cohort of 132 consecutive patients with EBUS-TBNA specimens showing NSCLC cells in lymph nodes. Data on patient demographics, radiology features of the suspected tumor and mediastinal engagement, lymph nodes sampled, the histopathological subtype of NSCLC, and performed molecular analysis were collected.

Results: The EBUS-TBNA specimen proved sufficient for subtyping NSCLC in 83% and analysis of treatment predictive biomarkers in 77% (MPS in 53%). The adequacy of the EBUS-TBNA specimen was 69% for EGFR gene mutation analysis, 49% for analysis of ALK rearrangement, 36% for ROS1 rearrangement, and 33% for analysis of PD-L1.

Conclusion: The findings of our study confirm that EBUS-TBNA cytology aspirate is appropriate for diagnosis and subtyping of NSCLC and largely also for treatment predictive molecular testing, although more data is needed on the utility of EBUS cytology specimen for MPS and PD-L1 analysis.

Disclosure of funding source(s):

Swedish Cancer Society (190473PjO1H),

Mrs. Berta Kamprads Foundation (FBKS-2020-7),

Crafoord's Foundation (20209975),

and Sjöberg's Foundation (2019-2011)